How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF
Paul Noble, MD, analyzes variables contributing to IPF or PPF disease prognosis.
Video content above is prompted by the following:
- How can a GAP (gender/age physiology) help determine patient prognosis with IPF or PPF?
- What are the risk factors for developing IPF or PPF and can patients be screened for the disease?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis
October 4th 2024Paul W. Noble, M.D., of Cedars-Sinai in Los Angeles, and Paul Frohna, M.D., Ph.D., of Endeavor BioMedicines, discussed the symptoms, epidemiology diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) in a Managed Healthcare Executive K-Cast video series.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
